Structural Formula (Pac0j 0000 01)
Chemical structure of Paclitaxel, showing its complex molecular arrangement with multiple rings and functional groups.*
Paclitaxel Injection, Solution
Product Images NDC 25021-255
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Paclitaxel (NDC 25021-255). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Pac0j 0000 02)
A Kaplan-Meier survival curve graph showing the proportion surviving over a period of up to 5 years. Two groups, labeled Cc and Tc, have survival curves plotted with the number at risk displayed at intervals. The graph includes a hazard ratio with 95% confidence interval and the number of events for each group.*
Figure 2 (Pac0j 0000 03)
A survival curve plot showing the proportion surviving over a period of 5 years. Two groups, labeled Cc and Tc, are compared with the number at risk indicated at various time points. An inset table provides sample sizes (N), number of events, and hazard ratio (HR) with 95% confidence interval (CI) for the comparison.*
Figure 3 (Pac0j 0000 04)
A Kaplan-Meier survival curve graph showing the proportion of patients disease-free over a period of 4 years. Two treatment groups are compared: AC and AC+T, with AC+T demonstrating a higher disease-free proportion. The graph includes a hazard ratio, number of events, and the number of patients at risk at various time points for both groups.*
Figure 4 (Pac0j 0000 05)
A survival curve chart showing the proportion surviving over a period of 4 years for two groups labeled AC and AC+T. The vertical axis represents the proportion surviving (0 to 1.0), and the horizontal axis represents years (0 to 4). Data on the number of participants at risk at various time points is displayed alongside a small table with number of events and hazard ratio (HR) comparing AC+T to AC groups.*
Figure 5 (Pac0j 0000 06)
A Kaplan-Meier survival curve chart depicting the proportion of patients disease-free over a 4-year period. It compares two groups labeled AC and AC+T, showing higher disease-free survival for AC+T. Numerical data includes sample sizes, number of events, hazard ratio, confidence interval, and number at risk over time.*
Figure 6 (Pac0j 0000 07)
A Kaplan-Meier survival curve graph showing the proportion of patients disease-free over a span of 4 years. The graph compares two groups labeled AC and AC+T, with the y-axis representing the proportion disease-free and the x-axis representing time in years. A table inset summarizes the number of patients, events, hazard ratio (HR) with 95% confidence interval (CI), and number at risk at different time points for both groups.*
Figure 7 (Pac0j 0000 08)
A Kaplan-Meier survival curve chart showing the proportion of patients disease-free over 4 years. The graph compares two groups labeled AC and AC+T, with lines depicting the disease-free proportion over time. The chart includes a table with sample sizes, number of events, hazard ratio (HR), confidence interval (CI), and number at risk by year for each group.*
Figure 8 (Pac0j 0000 09)
A Kaplan-Meier survival curve chart showing the proportion of patients disease free over a span of 4 years. Two treatment groups are compared: AC and AC+T, with the AC+T group consistently showing a higher disease-free proportion. The graph includes a risk table and hazard ratio (HR) data indicating the comparative effectiveness of treatments.*
Package Label – Principal Display Panel – Vial Label (Pac0j 0000 10)
Label for Paclitaxel Injection, USP 30 mg per 5 mL (6 mg per mL) sterile multi-dose vial by Sagent Pharmaceuticals. The label includes a caution for dilution before intravenous infusion and warns that the drug is a cytotoxic agent. It also lists ingredients and storage instructions, with the product made in India.*
Package Label – Principal Display Panel – Vial Label (Pac0j 0000 11)
Label for Paclitaxel Injection, USP 100 mg per 16.7 mL (6 mg per mL) solution for intravenous use. The multi-dose vial is labeled as a cytotoxic agent with a caution for dilution prior to infusion. Manufactured for Sagent Pharmaceuticals, the label includes storage instructions, ingredient details, and barcode.*
Package Label – Principal Display Panel – Vial Label (Pac0j 0000 12)
Label for Paclitaxel Injection USP 300 mg per 50 mL (6 mg per mL) solution for intravenous injection by Sagent Pharmaceuticals. The label shows dosage strength, volume, cautions about dilution prior to infusion, cytotoxic agent warning, storage instructions, components, manufacturing details, and a barcode. The product is sterile, preservative-free, and latex-free.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
